A deal with corporate angels

Noteworthy

One lesson that could be drawn from years of experience with very early stage research is that such work should be incubated in a non-corporate setting for as long as possible. Nevertheless, the lure of owning a piece of a biotech company remains strong, as evidenced by the announcement last week of a new virtual company, Helicon Therapeutics Inc.

Helicon is focused on development

Read the full 654 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE